Background Epidermal growth factor receptor inhibitors (EGFRI) produce various
dermatologic side effects in the majority of patients, and guidelines are crucial for the …

There has been a rapid emergence of numerous targeted agents in the oncology community
in the last decade. This exciting paradigm shift in drug development lends promise for the …

Highlights•This ESMO Clinical Practice Guideline provides recommendations on the
prevention/management of dermatological toxicities.•Authorship includes a multidisciplinary …

Inhibition of the epidermal growth factor receptor (EGFR) is an established treatment that
extends patient survival across a variety of tumor types. EGFR inhibitors fall into two main …

Targeting the epidermal growth factor receptor (egfr) pathway has become standard practice
for the treatment of advanced non-small-cell lung cancer. Compared with chemotherapy …

Purpose As epidermal growth factor receptor (EGFR) inhibitors are associated with a variety
of dermatologic adverse events (dAEs), the purpose of this study was to develop an …

Epidermal growth factor receptor (EGFR) inhibitors are widely used to treat various types of
cancers such as non-small cell lung cancer, head and neck cancer, breast cancer …

Background Afatinib has shown long progression free survival and improvement in quality of
life in advanced Non-Small Cell Lung Cancer (NSCLC) patients. Although afatinib causes …

Colorectal cancer (CRC) is an important public health issue, in terms of incidence and
mortality, with approximately 1.8 million new cases reported worldwide in 2018 …

Background. Agents targeting the epidermal growth factor receptor (EGFR) are amongst the
most extensively used of the targeted agents in the therapy of some of the most common …